Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IDH2-Post-Allo-Trial: Enasidenib As Consolidation or Salvage Therapy for Patients with IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation

NCT04522895 is registered in ClinicalTrials.gov with Heinrich-Heine University, Duesseldorf as lead sponsor.

NCT NCT04522895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04522895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IDH2-Post-Allo-Trial: Enasidenib As Consolidation or Salvage Therapy for Patients with IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation
Lead sponsor
Heinrich-Heine University, Duesseldorf
Phase
Phase 2
Overall status
Completed
Start date
August 27, 2020
Completion date
July 24, 2024
Enrollment
50 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, idh2 gene mutation, idh2 r140, idh2 r172, leukemia, myeloid, acute, myelodysplastic syndromes